Clinical Trials. Ongoing.

ELIAS Animal Health has developed a unique immunotherapy treatment protocol which may permit the dog’s immune system to attack its own cancer cells. ELIAS Cancer Immunotherapy (ECI®)—a vaccine-enhanced adoptive cell therapy—has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment.

Learn more about our clinical trials below.

Canine Oral Melanoma – Now Enrolling

Now enrolling a pilot study to evaluate the safety and efficacy of its adoptive T cell therapy combined with surgery and radiotherapy for dogs diagnosed with malignant oral melanoma.

Learn More

Canine Osteosarcoma

Enrollment for the canine osteosarcoma clinical study is now closed. Results will be available in 2022.

Learn More

“The T cell expansion is a huge component that, to my knowledge, none of the other autologous products are even trying to replicate.”

Zachary Wright, DVM, DACVIM (Oncology)

VCA Animal Diagnostic Clinic

Cancer Immunotherapy. Personalized

Our approach is profoundly simple: Every canine patient is unique. Every cancer is unique. To ultimately win against this devastating killer, cancer therapy itself must also be unique. ELIAS Cancer Immunotherapy (ECI®), our Autologous Prescription Product, harnesses the power of the dog’s own immune system to eliminate the cancer.

Killer T cells. Activated.

The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the capability to effectively kill cancer cells, including cancer stem cells. ELIAS cancer immunotherapy utilizes adoptive cell therapy to deliver an army of activated T cells.

Two Methods. Combined.

ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to kill the cancer.

Benefits. Expanded.

ELIAS’ cancer immunotherapy is a platform technology that has demonstrated effectiveness in multiple rodent and human cancers, while avoiding or minimizing the need for chemotherapy or radiation treatment. ELIAS is taking cancer treatment to new heights.

“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially and on average, based on that median survival. I will also point out that every single piece of the ELIAS immunotherapy process is extremely well supported in the scientific literature across multiple species.”

Jeffrey Bryan, DVM, DACVIM (Oncology)

University of Missouri

“There’s going to be a never-ending irreversible limitation of what autologous vaccine alone can do, which is why I’m attracted to the ECI product because of the activated T cell component. I don’t think that any of these products or autologous vaccines that are out there today are that much different or are going to offer that much significant difference. Whereas I think ECI has some clear improvements and should result in better results and better outcomes.”

K. Ann Jeglum, VMD, DACVIM (Oncology)

Veterinary Oncology Services and Research Center